Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Times Interest Earned (2016 - 2025)

Historic Times Interest Earned for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $60.36.

  • Ligand Pharmaceuticals' Times Interest Earned rose 132314.76% to $60.36 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6, marking a year-over-year increase of 16420.01%. This contributed to the annual value of -$7.44 for FY2024, which is 14088.89% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Times Interest Earned of $60.36 as of Q3 2025, which was up 132314.76% from $7.32 recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Times Interest Earned high stood at $3078.0 for Q3 2023, and its period low was -$83.75 during Q4 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' median Times Interest Earned value was $4.24 (recorded in 2024), while the average stood at $164.63.
  • Its Times Interest Earned has fluctuated over the past 5 years, first tumbled by 109210.7% in 2022, then soared by 818049.59% in 2023.
  • Ligand Pharmaceuticals' Times Interest Earned (Quarter) stood at $8.44 in 2021, then plummeted by 1092.11% to -$83.75 in 2022, then soared by 69.39% to -$25.63 in 2023, then surged by 57.42% to -$10.91 in 2024, then skyrocketed by 653.09% to $60.36 in 2025.
  • Its Times Interest Earned stands at $60.36 for Q3 2025, versus $7.32 for Q2 2025 and -$41.77 for Q1 2025.